Argus raises Cardinal Health stock price target on strong earnings

Argus raised its price target for Cardinal Health (CAH) to $309 from $264, citing strong Q1 2027 results. The company reported 5% revenue growth and 28% adjusted EPS growth to $3.26, exceeding estimates. Cardinal Health also raised its fiscal 2027 adjusted EPS guidance to $12.80-$13.00. The stock is near its 52-week high, up 53% in six months, and is considered undervalued by InvestingPro.

Original reporting
Published Nov 12, 2026, 1:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 1:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CAH
Bullish
high confidence
Mentioned
$CAH
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CAHBullishHigh
01

Why it matters

The earnings beat and guidance lift suggest stronger cash flow, supporting dividend sustainability and possible share buybacks.

02

Market read

The report provides fresh, material data that can move the stock and influences sector sentiment.

03

What to watch

Potential headwinds from drug pricing pressures and supply‑chain constraints could temper upside.

Relevance 8/10Novelty 8/10Timing: immediate, same‑day reaction

Background

Cardinal Health is a major distributor of pharmaceuticals and medical products in the United States.

Company-level read

Ticker impact

$CAHBullishHigh confidence
Context

Cardinal Health reported Q1 FY2027 results beating estimates and raised FY2027 EPS guidance to $12.80‑$13.00, prompting analyst price‑target hikes.

Expected impact

upward pressure as investors price in higher earnings outlook and raised price targets

Evidence & confidence

Earnings beat, 5% revenue growth, 28% EPS growth and guidance lift are material new information for a large‑cap health‑services stock.

Market effects

Boosts outlook for pharmaceutical distribution and specialty services sector.

Positive for U.S. healthcare services equities.

Limited to U.S. market; no direct global ripple.

Counterpoint

If the guidance raise is already priced in, the stock may face short‑term profit‑taking.

Key entities

  • Cardinal Health

    U.S. healthcare services and distribution firm.

  • Argus Research

    Raised price target to $309 on the earnings beat.

Related articles

$CAHHighAI 8/10

Cardinal Health Q1 Earnings Call Highlights

Cardinal Health (CAH) raised its full-year pharmaceutical segment profit growth forecast to 10-12% and maintained revenue growth outlook of 3-5%. CEO Jason Hollar highlighted contract renewals, including a long-term agreement with CVS Health. Medical unit revenue was flat at $3.2B, but profit exceeded expectations. The company raised its annual revenue and profit growth forecasts for its 'other' category, citing strong demand.

$CAHHighAI 8/10

Cardinal Health Raises Fiscal 2027 Growth Targets for Two Segments

Cardinal Health raised its fiscal 2027 earnings forecast after Q1 non-GAAP EPS rose 28% to $3.26. Revenue increased 5% to $67.513 billion. Pharmaceutical and Specialty Solutions revenue grew 6%, while Global Medical Products and Distribution revenue was flat. The company also completed $500 million in share repurchases.

$CAHHighAI 8/10

Cardinal Health Inc (CAH) (Q1 2027) Earnings Call Highlights: Record $1 Billion

Cardinal Health (CAH) reported Q1 2027 earnings with record operating income of $1 billion. GMPD segment revenue was flat at $3.2B, with full-year profit expected toward the low end of $200-$220M due to high petroleum costs. Pharmaceutical revenue growth faced headwinds from IRA WAC reductions, partially offset by GLP-1 growth. Earnings growth is expected to moderate in Q2 and Q3 before strengthening in Q4. The company raised its fiscal 2027 EPS guidance to $12.80-$13.00, up from $12.40-$12.60.

$CAHHighAI 8/10

Cardinal Health (CAH) Q1 2027 Earnings Call Transcript

Cardinal Health (CAH) reported Q1 2027 revenue of $67.5B (+5% YoY) and raised fiscal 2027 EPS guidance to $12.80-$13.00. The company renewed its contract with CVS Health (CVS) through 2032, securing long-term stability. Pharma segment revenue grew 6%, while GMPD revenue was flat. Profit increased across all segments, with operating income reaching $1B. The company repurchased $500M in shares and maintained strong cash flow.

$CAHHighAI 8/10

We're raising our price target on Cardinal Health after another stellar quarter of profits

Cardinal Health (CAH) reported Q1 FY2027 revenue of $67.51B (+4% YoY) and adjusted EPS of $3.26 (+28% YoY), beating estimates. The company raised its full-year EPS guidance to $12.80-$13.00. Shares rose over 3% on the news. CEO Jason Hollar highlighted strong demand in the Pharmaceutical and Specialty Solutions segment. The company also repurchased $500M in stock. Analysts raised the price target to $300 from $265.